MMP-2
MMP-2 (matrix metalloproteinase-2), also known as gelatinase A, is a zinc-dependent extracellular endopeptidase that plays a central role in extracellular matrix remodeling through the degradation of gelatin, type IV collagen, and other basement membrane components[6][7]. Mechanistically, MMP-2 is synthesized as a latent proenzyme and is activated at the cell surface through the MT1-MMP/TIMP-2/pro-MMP-2 activation complex, linking its proteolytic activity to tightly regulated pericellular signaling and matrix turnover[1][2]. Through these functions, MMP-2 contributes to cell migration, tissue remodeling, angiogenesis, and inflammatory regulation, making it an important mediator of both physiological repair processes and pathological tissue remodeling[6][7]. Dysregulated MMP-2 expression or activation has been associated with cancer progression, cardiovascular disorders, kidney disease, diabetic complications, and fibrotic conditions, where excessive extracellular matrix degradation promotes disease development and tissue dysfunction[6]. In tumor models, elevated MMP-2 activity correlates with invasive behavior, metastatic dissemination, and angiogenic remodeling, supporting its widespread use as a biomarker and mechanistic target in cancer research[3][4]. Compared with the closely related gelatinase MMP-9, MMP-2 is constitutively expressed in many tissues and is preferentially regulated through MT1-MMP- and TIMP-2-dependent activation mechanisms, whereas MMP-9 is more commonly induced by inflammatory stimuli and exhibits distinct substrate and regulatory profiles[7]. For experimental applications, broad-spectrum metalloproteinase inhibitors such as batimastat have been widely used to investigate MMP-2-dependent signaling and matrix remodeling, although selective targeting remains an active area of therapeutic development[5].
References:
- [1]. Khurana S, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med. 2011 Jun 1;3(85):85ra48. [Content Brief]
- [2]. Heidenfelder BL, et al. Hairpin formation in Friedreich's ataxia triplet repeat expansion. J Biol Chem. 2003 Jan 24;278(4):2425-31. [Content Brief]
- [3]. Forsyth PA, et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer. 1999 Apr;79(11-12):1828-35. [Content Brief]
- [4]. Johnson M, et al. Multiple triangulation and collaborative research using qualitative methods to explore decision making in pre-hospital emergency care. BMC Med Res Methodol. 2017 Jan 24;17(1):11. [Content Brief]
- [5]. Chang M. Matrix metalloproteinase profiling and their roles in disease. RSC Adv. 2023;13:6304-6316.
- [6]. Wolosowicz M, et al. The Complex Role of Matrix Metalloproteinase-2 (MMP-2) in Health and Disease. Int J Mol Sci. 2024;25(24):13691.
- [7]. Nikolov A, et al. Role of gelatinases MMP-2 and MMP-9 in healthy and complicated pregnancy and their future potential as preeclampsia biomarkers[J]. Diagnostics, 2021, 11(3): 480.
-
MMP-2 Related Products (148)
Related Products (148)
-
Recombinant Proteins (7)
-
Antibodies (1)
-
MMP-2 Inhibitor I
0 ImagesMMP-2 Inhibitor I (OA-Hy) is a potent MMP-2 inhibitor with a Ki of 1.7 μM.
-
Alisol A
0 ImagesAlisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity.
-
ND-336
0 ImagesCat. No.: HY-124373CAS No.: 1807453-83-3
-
TMI-1
0 ImagesSynonyms: WAY-171318TMI-1 (WAY-171318) inhibits TNF converting enzyme (TACE) (IC50 of 8.4 nM), ADAM-TS-4, ADAM-17 and various MMPs with oral activity. TMI-1 significantly suppresses the secretion of TNF-α , alleviating collagen-induced arthritis in mice. TMI-1 inhibits cancer cell proliferation, induces apoptosis through a caspase-dependent pathway. TMI-1 also reverses TRPV1 upregulation and lowers the levels of inflammatory factors (TNF-α、IL-1β、IL-6) in nerve cells, protecting against paclitaxel-induced neurotoxicity. TMI-1 leads to changes in pro-atherogenic lipoprotein profiles, but does not affect the progression of early lesions.
-
α-Glucosylrutin
0 ImagesCat. No.: HY-164159CAS No.: 130603-71-3α-Glucosylrutin, a flavonoid, is a potent antioxidant with free radical scavenging activity. α-Glucosylrutin reduces MMP-1 gene expression, protein expression, and enzyme activity, and reduces MMP-2 protein expression and enzyme activity in UVA-irradiated human dermal fibroblasts. α-Glucosylrutin prevents oxidative stress-induced intracellular tyrosine residue phosphorylation and counteracts intracellular thiol level depletion in human skin cells. α-Glucosylrutin is effective in the prevention of dermatologic diseases in which oxidative stress is of pathogenetic relevance, e.g. in polymorphous light eruption (PLE). α-Glucosylrutin can be used for the research of UV-induced skin photodamage/photoaging.
-
BI-4394
0 ImagesSynonyms: MMP13-IN-3BI-4394 (MMP13-IN-3), a chemical probe, is a potent, selective, and orally active MMP-13 inhibitor (IC50=1 nM) for the potential treatment of osteoarthritis. BI-4394 is >1000 selective over other MMPs.
-
AK-778-XXMU
0 ImagesAK-778-XXMU is a potent DNA binding inhibitor 2 (ID2) antagonist with a KD of 129 nM. AK-778-XXMU can inhibit cell migration and invasion of glioma cell lines, induce apoptosis, and exhibits significant cancer-suppressing potency. AK-778-XXMU inhibits the ID2-KDR signaling axis, thereby down-regulating the downstream angiogenic factors (VEGFA) and invasion-related proteins (MMP2/9), and up-regulating the tumor suppressor factor (PTEN). AK-778-XXMU can be used for the study of glioma.
-
Prinomastat
0 ImagesSynonyms: AG3340; KB-R9896Prinomastat (AG3340) is a broad spectrum, potent, orally active metalloproteinase (MMP) inhibitor with IC50s of 79, 6.3 and 5.0 nM for MMP-1, MMP-3 and MMP-9, respectively. Prinomastat inhibits MMP-2, MMP-3, MMP-13 and MMP-9 with Kis of 0.05 nM, 0.3 nM, 0.03 nM and 0.26 nM, respectively. Prinomastat crosses blood-brain barrier. Antitumor avtivity.
-
Sorafenib (Standard)
0 ImagesSynonyms: Bay 43-9006 (Standard)Sorafenib (Standard) (Bay 43-9006 (Standard)) is the analytical standard of Sorafenib (HY-10201). This product is intended for research and analytical applications. Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
-
Ecliptasaponin A
0 ImagesEcliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors.
-
MMP13-IN-2
0 ImagesMMP13-IN-2 is a potent, selective and orally active MMP-13 inhibitor. MMP13-IN-2 exhibits excellent potency for MMP-13 (IC50=0.036 nM) and selectivities (greater than 1,500-fold) over MMP-1, 3, 7, 8, 9, 14, and TACE. MMP13-IN-2 has the ability to block the release of collagen from cartilage in vitro. MMP13-IN-2 has the potential for collagenase related disease research.
-
Quercimeritrin
0 ImagesQuercimeritrin (Quercetin-7-O-β-D-glucopyranoside) is an orally active α-glucosidase inhibitor (with an IC50 of 79.88 μM against the Saccharomyces cerevisiae enzyme) and a P-gp substrate, with anti-angiogenic and antioxidant activities. Quercimeritrin does not cross the blood-brain barrier and does not inhibit cytochrome P450 enzymes. Quercimeritrin precisely binds to and inhibits the active sites of c-Kit, MMP-2, Aurora-A kinases and α-glucosidase, thereby disrupting target functions. Quercimeritrin effectively regulates postprandial blood glucose and also exhibits significant anti-angiogenic activity, which inhibits endothelial cell proliferation and microvascular growth. Quercimeritrin can be used in the research of diabetes and breast cancer.
-
Trilinolein
0 ImagesTrilinolein is an orally active triglyceride that inhibits the PI3K/Akt, Ras/MEK/ERK signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer.
-
Indinavir
0 ImagesSynonyms: MK-639 free base; L-735524 free baseIndinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a SARS-CoV 3CLpro inhibitor.
-
PT109
0 ImagesPT109 is an orally active, blood-brain barrier permeable multi-kinase inhibitor. By inhibiting PTBP1, PT109 promotes the switch of pyruvate kinase isoform from PKM2 to PKM1, thereby effectively inhibiting the proliferation and migration of glioblastoma multiforme and inducing its reprogramming into oligodendrocytes. PT109 also targets and regulates key signaling molecules such as JNK, SGK1, GSK3β to exert neuroprotective effects including promoting neurogenesis, inducing synapse formation and alleviating neuroinflammation. In Alzheimer's disease models, PT109 exhibits significant efficacy in improving spatial learning ability, along with excellent in vivo pharmacokinetic properties. PT109 can be used to investigate metabolic reprogramming of glioblastoma multiforme and neuroprotective mechanisms of Alzheimer's disease.
-
PLGLAG
0 ImagesPLGLAG is a peptide that serves as the linker in activatable cell-penetrating peptides (ACPPs) and can be used in cancer research.
